Literature DB >> 21541674

Matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) in preoperative serum as independent prognostic markers in patients with colorectal cancer.

Vesna V Dragutinović1, Nevena V Radonjić, Nataša D Petronijević, Svetislav B Tatić, Ivan B Dimitrijević, Nebojša S Radovanović, Zoran V Krivokapić.   

Abstract

Colorectal cancer is one of the leading causes of cancer related death in developed countries. One of the reasons is the absence of tumor specific diagnostic and prognostic markers. The aim of this study was to examine the correlation of matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) expressions in serum and clinicopathological features of the colorectal adenocarcinoma. Another aim was to examine expression of MMP-9 in the tissue of the colorectal carcinoma in MMP-9 serum positive patients. In addition, we tried to establish the correlation between preoperative levels of serum markers (CEA and CA 19-9) and presence of MMP-2 or MMP-9. The study was performed on 32 patients with colorectal adenocarcinoma who underwent surgery and 11 patients in a control group who were operated for benign diseases. The samples were analyzed by SDS-PAGE to determine the molecular mass and SDS-PAGE zymography to determine levels of MMP-2 and MMP-9. Expression of MMP-9 was determined immunohistochemically in the tissue of the colorectal carcinoma of MMP-9 serum positive patients. MMP-2 and MMP-9 levels were increased in the serum of the patients with colorectal cancer compared to the control group. There was significant correlation in MMPs levels among the patients with tumor stage I and II and the patients with tumor stage III and IV. Obtained results did not demonstrate correlation between levels of CEA, CA 19-9 and presence of MMP-2 or MMP-9. MMP-9 expression was positive in 85% of MMP-9 serum positive patients with colorectal carcinoma. The overexpression of MMP-2 and MMP-9 strongly suggests its association with colorectal adenocarcinoma. Detection of MMP-2 and MMP-9 in serum might be useful for identification of patients with higher risk for colorectal cancer recurrence.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21541674     DOI: 10.1007/s11010-011-0851-0

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  34 in total

1.  Serum or plasma samples? The "Cinderella" role of blood collection procedures: preanalytical methodological issues influence the release and activity of circulating matrix metalloproteinases and their tissue inhibitors, hampering diagnostic trueness and leading to misinterpretation.

Authors:  Ferdinando Mannello
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-04       Impact factor: 8.311

2.  Plasma concentration of matrix metalloproteinase 9 in gastric cancer.

Authors:  A Torii; Y Kodera; K Uesaka; T Hirai; K Yasui; T Morimoto; Y Yamamura; T Kato; T Hayakawa; N Fujimoto; T Kito
Journal:  Br J Surg       Date:  1997-01       Impact factor: 6.939

Review 3.  Matrix metalloproteinases in tumour invasion and metastasis.

Authors:  S Curran; G I Murray
Journal:  J Pathol       Date:  1999-11       Impact factor: 7.996

4.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

5.  Plasma matrix metalloproteinase-9 level is better than serum matrix metalloproteinase-9 level to predict gastric cancer evolution.

Authors:  Chun-Ying Wu; Ming-Shiang Wu; En-Pei Chiang; Yi-Ju Chen; Chien-Jen Chen; Nai-Hui Chi; Ying-Ting Shih; Gran-Hum Chen; Jaw-Town Lin
Journal:  Clin Cancer Res       Date:  2007-04-01       Impact factor: 12.531

6.  Serum matrix metalloproteinase-9 level associated with stromal reaction in patients with gastric cancer.

Authors:  K H Shen; C W Chi; S S Lo; H L Kao; W Y Lui; C W Wu
Journal:  Anticancer Res       Date:  2000 Mar-Apr       Impact factor: 2.480

7.  Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma.

Authors:  Raquel F Gerlach; Caroline Demacq; Klaus Jung; Jose E Tanus-Santos
Journal:  Clin Biochem       Date:  2006-10-19       Impact factor: 3.281

8.  Matrix metalloproteinase-9 expression in the normal mucosa-adenoma-dysplasia-adenocarcinoma sequence of the colon.

Authors:  László Herszényi; Ferenc Sipos; Orsolya Galamb; Norbert Solymosi; István Hritz; Pál Miheller; Lajos Berczi; Béla Molnár; Zsolt Tulassay
Journal:  Pathol Oncol Res       Date:  2008-03-18       Impact factor: 3.201

9.  Distribution of gelatinase B (MMP-9) and type IV collagen in colorectal carcinoma.

Authors:  M Jeziorska; N Y Haboubi; P F Schofield; Y Ogata; H Nagase; D E Woolley
Journal:  Int J Colorectal Dis       Date:  1994-08       Impact factor: 2.571

10.  Relation of matrix metalloproteinase-9 to different stages of tumors in the serum of gastric cancer.

Authors:  V Dragutinović; L Izrael-Zivković; N Radovanović
Journal:  Dig Dis Sci       Date:  2008-08-23       Impact factor: 3.199

View more
  21 in total

1.  MMP-9 polymorphisms are related to serum lipids levels but not associated with colorectal cancer susceptibility in Chinese population.

Authors:  Zhi-Hui Yang; Shi-Ning Li; Jin-Xing Liu; Qing-Xi Guo; Xing-Wang Sun
Journal:  Mol Biol Rep       Date:  2012-06-24       Impact factor: 2.316

2.  Prognostic value of interleukin-8 and MMP-9 in nasopharyngeal carcinoma.

Authors:  Daye Cheng; Hong Kong; Yunhui Li
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-06-09       Impact factor: 2.503

3.  APRIL induces tumorigenesis and metastasis of colorectal cancer cells via activation of the PI3K/Akt pathway.

Authors:  Guihua Wang; Feng Wang; Weifeng Ding; Jingchun Wang; Rongrong Jing; Haiquan Li; Xudong Wang; Yueguo Wang; Shaoqing Ju; Huimin Wang
Journal:  PLoS One       Date:  2013-01-29       Impact factor: 3.240

4.  Correlation and prognostic significance of MMP-2 and TFPI-2 differential expression in pancreatic carcinoma.

Authors:  Lu-Lu Zhai; Chong-Yang Cai; Yang Wu; Zhi-Gang Tang
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 5.  Impact of proteolytic enzymes in colorectal cancer development and progression.

Authors:  László Herszényi; Loránd Barabás; István Hritz; Gábor István; Zsolt Tulassay
Journal:  World J Gastroenterol       Date:  2014-10-07       Impact factor: 5.742

6.  Silibinin inhibits the migration and invasion of human gastric cancer SGC7901 cells by downregulating MMP-2 and MMP-9 expression via the p38MAPK signaling pathway.

Authors:  Shuming Lu; Zhuqing Zhang; Meiru Chen; Chunyan Li; Lina Liu; Yan Li
Journal:  Oncol Lett       Date:  2017-09-27       Impact factor: 2.967

Review 7.  Gut microbiome influences on anastomotic leak and recurrence rates following colorectal cancer surgery.

Authors:  S Gaines; C Shao; N Hyman; J C Alverdy
Journal:  Br J Surg       Date:  2018-01       Impact factor: 6.939

8.  Serum matrix metalloproteinase 9 and colorectal neoplasia: a community-based evaluation of a potential diagnostic test.

Authors:  S Wilson; S Damery; D D Stocken; G Dowswell; R Holder; S T Ward; V Redman; M J Wakelam; J James; F D R Hobbs; T Ismail
Journal:  Br J Cancer       Date:  2012-03-20       Impact factor: 7.640

Review 9.  The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer.

Authors:  László Herszényi; István Hritz; Gábor Lakatos; Mária Zsófia Varga; Zsolt Tulassay
Journal:  Int J Mol Sci       Date:  2012-10-16       Impact factor: 5.923

10.  Assessing the value of matrix metalloproteinase 9 (MMP9) in improving the appropriateness of referrals for colorectal cancer.

Authors:  S Damery; L Nichols; R Holder; S T Ward; S Warmington; S Wilson; M J Wakelam; J James; T Ismail
Journal:  Br J Cancer       Date:  2013-02-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.